LYEL · Lyell Immunopharma, Inc.

0001628280-26-031284

Summary

Operating and net losses narrowed year-over-year through cost discipline following the 2025 ronde-cel technology transfer, despite a sharp revenue decline and ongoing cash use from clinical development investments.

Key takeaways

Revenue declined 71.4% to $2K from $7K, consistent with limited collaboration revenue in pre-commercial clinical-stage biotech.
Net loss improved 53.7% to -$24.2M from -$52.2M, reflecting better operating results and lower interest expense.
Diluted EPS worsened to -$1.10 from -$0.18 due to the smaller revenue base amplifying per-share losses.

Full analysis

Lyell Immunopharma reported Q1 2026 results reflecting continued investment in its clinical cell therapy pipeline amid post-manufacturing transfer cost efficiencies. Revenue fell 71.4% year-over-year to $2.0 thousand from $7.0 thousand, typical for a pre-commercial biotech with minimal collaboration income as focus remains on advancing product candidates like those leveraging CD62L-positive T cells for improved CAR T expansion, persistence, and reduced exhaustion versus traditional processes.